Bosh sahifaCGEN • NASDAQ
add
Compugen Ltd
1,41 $
Seans yopilganidan keyin:(0,00%)0,00
1,41 $
Yopilgan:22-noy, 17:11:33 (GMT-5) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
1,45 $
Kunlik diapazon
1,38 $ - 1,50 $
Yillik diapazon
0,62 $ - 3,03 $
Bozor kapitalizatsiyasi
126,25 mln USD
Oʻrtacha hajm
252,97 ming
Narx/foyda
73,55
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 17,13 mln | — |
Joriy xarajat | 9,04 mln | -14,99% |
Sof foyda | 1,28 mln | 112,95% |
Sof foyda marjasi | 7,45 | — |
Har bir ulushga tushum | 0,01 | 109,09% |
EBITDA | 4,62 mln | 143,92% |
Amaldagi soliq stavkasi | 77,92% | — |
Balans
Jami aktivlari
Jami passivlari
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 112,71 mln | 95,99% |
Jami aktivlari | 123,52 mln | 82,69% |
Jami passivlari | 63,03 mln | 338,18% |
Umumiy kapital | 60,49 mln | — |
Tarqatilgan aksiyalar | 89,54 mln | — |
Narxi/balansdagi bahosi | 2,13 | — |
Aktivlardan daromad | 9,62% | — |
Kapitaldan daromad | 18,01% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(USD) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | 1,28 mln | 112,95% |
Operatsiyalardan naqd pul | — | — |
Sarmoyadan naqd pul | — | — |
Moliyadan naqd pul | — | — |
Naqd pulning sof oʻzgarishi | — | — |
Boʻsh pul | — | — |
Haqida
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. Wikipedia
Tashkil etilgan
10-fev, 1993
Sayt
Xodimlar soni
68